Four examples of Prime Ministerial power – how Boris Johnson in fact ‘did everything he could’ for there to be a trade barrier down the Irish Sea

4th February 2021

You will no doubt have an opinion on Boris Johnson, the current prime minister of the United Kingdom.

For my part, the best and most insightful depictions of Johnson as a politician are this piece by Marina Hyde and this by Rafael Behr.

This post, however, will look at the prime minister not just as politician but also through the lens of constitutional law and practice – and, in particular, will examine one statement he made yesterday.

Everyone who cares knows that Johnson will not do – and has not done – ‘everything’ to avoid a barrier down the Irish Sea.

The fact that this statement is untrue is by itself neither here nor there: more than most politicians, Johnson knowingly says false things.

But for this blog, what is interesting about this lie is that its falsity engages four distinct examples of prime ministerial power.

For Johnson did everything as a prime minister for there to be a barrier down the Irish Sea.

*

Within a parliamentary system such as the United Kingdom, and with the constitutional theory that executive power flows from the crown, there are limits to what any prime minister can and cannot do.

But the Irish barrier question shows the ways in which a prime minister can exercise power.

*

First, a prime minister can change and set government policy.

And here Johnson broke with the policy of his predecessor on the (once infamous) ‘backstop’ in the withdrawal agreement.

Johnson, of course, did this for cynical reasons of political convenience – but it is a decision that only a prime minister could have made.

And Johnson did.

*

Second, a prime minister can enter into international agreements.

In constitutional theory, this is the prime minster using the royal prerogative to enter into those international agreements.

So having reversed the policy of his predecessor, he proceeded to agree the withdrawal agreement providing for a trade barrier down the Irish Sea.

And again, this was something he could only have done as prime minister.

*

Third, a prime minister – as leader of the party that wins a general election – can win a mandate for their policies.

Currently, calling a general election is outside the powers of a prime minister, by reason of the Fixed-term Parliaments Act.

But when there is a general election, and that election is won, the prime minister (and the winning party) then enjoys a mandate for their manifesto commitments.

And this mandate is constitutionally significant – for example: any policy with such a mandate cannot be blocked or delayed by the house of lords.

The (then) ‘oven-ready’ deal was mandated by the 2019 general election.

So, again, a mandate was something Johnson achieved as a prime minister (and which his predecessor failed to do with the 2017 general election).

*

And fourth, a prime minister is ultimately responsible for the government’s programme of legislation.

So: having reversed policy, entered into an agreement with the European Union giving effect to that new policy, and having won a mandate for the policy in a general election…

…the prime minister now ensured that the policy was implemented into domestic law with an act of parliament.

(Legislation that, of course, was pushed through with minimal scrutiny using the government’s newly obtained overall majority so as to ‘Get Brexit Done’).

*

That there is now a trade barrier in the Irish Sea is a perfect illustration of the various powers of a prime minister under our constitutional arrangements.

The trade barrier in the Irish Sea was Boris Johnson’s policy (which he reversed from his predecessor), which he agreed with the European Union and for which won a mandate in a general election, and that he then ensured was enacted into domestic law.

There was nothing more Johnson as prime minister could have done for there to be this trade barrier in the Irish Sea.

*****

If you value this free-to-read and independent legal and policy commentary please do support through the Paypal box above, or become a Patreon subscriber.

Each post takes time, effort, and opportunity cost.

Suggested donation of any amount as a one-off, or of £4.50 upwards on a monthly profile.

This law and policy blog provides a daily post commenting on and contextualising topical law and policy matters – each post is usually published at about 9.30am UK time – though some special posts are published later.

*****

You can also subscribe for each post to be sent by email at the subscription box above (on an internet browser) or on a pulldown list (on mobile).

*****

Comments Policy

This blog enjoys a high standard of comments, many of which are better and more interesting than the posts.

Comments are welcome, but they are pre-moderated.

Comments will not be published if irksome.

How Theresa May casually decided that Brexit meant the United Kingdom would leave the single market and customs union – the fascinating and revealing interview with Philip Hammond

3rd February 2021

One response to the news that former chancellor Philip Hammond has given a candid and critical interview about the Brexit policy (or lack of policy) of the Theresa May administration is to sneer and jeer, announce that he should have resigned rather than be party to it, and to ‘like” and RT some tweet saying so.

And then to not give it a further thought.

Another, more worthwhile reaction is to look out the interview, and to read and consider it carefully.

And in doing so, you should compare what Hammond says now with your recollection of what Brexit seemed like at the time, from the outside.

What emerges is a picture that many of us onlookers – conscious of the issues at stake but unimpressed by the government’s shallow public messaging – suspected was true all along.

The interview – which is part of an impressive series of interviews with ‘witnesses’ of Brexit by UK in a Changing Europe – should be read in full by anyone wanting a real understanding of what happened within government on Brexit.

But below are some examples which, at least for me and my commentary, substantiated what some of us believed to be the case at the time – including about the casual nature of the huge decision to leave the single market and the customs union.

The transcript of the interview is here.

*

On the creation of the pop-up government departments, the Department for Exiting the European Union and the Department for International Trade, Hammond says:

‘Creating a new Government department, frankly, is a pretty cost-free signalling mechanism for an incoming Prime Minister. So, the Department for Exiting the European Union – a ludicrous notion, absolutely ludicrous; a rookie civil service trainee could tell you that that was a stupid idea – and the Department for International Trade, were both gestures.

‘They were ways of bringing in clear, committed Brexiteers to the Government, and plonking them in a place where they could assert their views, rally their troops, and, she hoped, provide a focal point for the hard-line Brexiteers in the parliamentary party. As well as finding out the hard way how difficult this was all going to be in practice.’

*

On the botched re-negotiation that preceded the referendum (which was so limited because it misunderstood what the European Union could offer without a treaty change):

‘We all interpreted German pragmatism as support for a more British view of the future of Europe. That was clearly not correct, so we definitely overestimated the flexibility of the Europeans.’

*

And perhaps most significantly, on the run-up to the fateful October 2016 conservative party speech in Birmingham – and its aftermath:

‘I was completely stunned by the speech that she made at the Conservative Party Conference in October 2016. I hadn’t seen the relevant part of it in advance. I’d had no input to the speech. Nick Timothy kept me completely away from it. […]

‘I was completely and utterly horrified by what I felt was almost a coup: a definition of Brexit without any proper Cabinet consultation at all. 

‘My assessment of Theresa May’s Prime Ministership, in terms of Brexit, is that she dug a 20-foot-deep hole in October 2016 in making that speech and, from that moment onwards, cupful by cupful of earth at a time, was trying to fill it in a bit so that she wasn’t in such a deep mess. […]

‘It was a disaster on all fronts, a total unmitigated disaster that scarred her Prime Ministership and should have sealed Nick Timothy’s fate, but I think she only realised later how badly that had constrained her ability to deliver any kind of practical Brexit at all.’

*

What this interview indicates – if not demonstrates – is how crucial those first few months were after the referendum were to the shape of Brexit, from June to October 2016.

That was when, in my view, the battle for Brexit was won and lost.

Until the conference speech it was possible to conceive of a number of different possible Brexits that could follow the referendum result.

(Or in my (incorrect) view at the time, that it was possible that the thing would just be delayed and delayed, as the sheer magnitude of the task became scarily apparent.)

But after the October speech, the only Brexit which was politically likely would be the absolute version with the United Kingdom leaving the single market and the customs union.

And the only way that such a Brexit could have been stopped, again in my view, would have been if the respective leaders of the labour, liberal democrat and other opposition parties had handled the prospect of a general election differently in late 2019.

In essence: in the whole of the story of Brexit so far, only (a) June to October 2016 and (b) November/December 2019 were the real turning points where Brexit could have turned out substantially different after the referendum.

The interview with Hammond, in particular, reminds us that there were non-Brexiter ‘pragmatists’ as well as (in his word) ‘refuseniks’ in those first few months after the referendum.

And notwithstanding the ‘Brexit means Brexit’ slogan of May in her party leadership bid of that summer, it was still possible to conceive of different outcomes.

The pragmatists could have prevailed.

But.

But something happened – a decision was casually made that will turn out to be as consequential for the United Kingdom as any other immensely important decision in our history.

And that decision was made by a prime minister who, on Hammond’s account, did not understand the import of her decision, and without reference to either cabinet or parliament.

An extraordinary moment, and one which is becoming more extraordinary over time.

*****

If you value this free-to-read and independent legal and policy commentary please do support through the Paypal box above, or become a Patreon subscriber.

Each post takes time, effort, and opportunity cost.

Suggested donation of any amount as a one-off, or of £4.50 upwards on a monthly profile.

This law and policy blog provides a daily post commenting on and contextualising topical law and policy matters – each post is usually published at about 9.30am UK time – though some special posts are published later.

*****

You can also subscribe for each post to be sent by email at the subscription box above (on an internet browser) or on a pulldown list (on mobile).

*****

Comments Policy

This blog enjoys a high standard of comments, many of which are better and more interesting than the posts.

Comments are welcome, but they are pre-moderated.

Comments will not be published if irksome.

For every Bingham there will be many more Hardings – why the law of public procurement matters – by a partial and prejudiced public procurement lawyer

2nd February 2021

Like constitutional law and practice, the law and practice of public procurement has recently been exciting.

And this is not a good thing, for also like constitutional law and practice, the law and practice of public procurement should be dull.

But unlike constitutional law and practice – the elements of which like the crown, parliament and the courts are at least well known – the elements of the law and practice of public procurement are not so well known.

Indeed, many commercial and public lawyers can go through their careers and never have to deal with a public procurement issue.

And many commercial companies – all potential government suppliers – will never engage with the public sector.

Public procurement is (usually) a minority interest.

*

But.

Public procurement – that is, in general terms, the purchase by public bodies of goods and services and works (that is, major projects) from the private sector – has become rather politically controversial.

And with Brexit, this public prominence is likely to continue.

So it seemed worthwhile to set out to non-lawyers – and other lawyers with no direct connection with public procurement – to set out some basic points about public procurement, from the subjective perspective of someone who has had some experience in public procurement for twenty years.

*

The starting point, at least in the United Kingdom, is that central government would in principle be able to lawfully buy anything from anyone at any price and on any terms – but for the law of public procurement.

This is because – and here comes some constitutional law mumbo-jumbo – the crown is regarded as a legal person with full capacity.

And just as you and I are able, as natural persons, to enter into contracts, so is the crown.

Of course, it is not Elizabeth Mountbatten-Windsor who is signing contracts for things from toilet rolls to nuclear submarines as part of some extraordinary Waitrose delivery.

But in principle, the crown is able to enter into any contractual obligations it so wishes.

The agreements are, in turn, usually entered into on the crown’s behalf by government departments – usually in the name of the relevant secretary of the state.

(Here it can get complicated, as many secretaries of state are regarded by the law as ‘corporations sole’ that can hold property and so on.)

And so this means that government departments are, in principle, are able to enter into any contractual obligations they so wish.

Apart from central government, there are many other public bodies with a mix of legal forms – from bodies established by royal charter to corporations set up by statute – and these bodies also can, in (very) general terms, enter into contracts as readily as any natural person.

(There used to be many cases where certain transactions were held to be ‘ultra vires’ the powers of local authorities, but legal changes have meant that this is less likely to be the case now.)

And this is the basis of the law of public procurement in the United Kingdom: that but for the law of public procurement, public bodies can in general lawfully enter into transactions freely.

In this way, the law and practice of public procurement should primarily be seen as like the ropes around Lemuel Gulliver or King Kong – preventing public bodies from doing what they otherwise would do.

*

So what are the restraints of public procurement?

In theory, the restraints are of two kinds.

First, there are general principles – at least under the law of the European Union (which has now been adopted as domestic law) and the rules of the World Trade Organisation.

Tenders should be advertised and open to all-comers; selection criteria should be published; public bodies should not discriminate in favour of incumbents and domestic companies; tenderers should be treated equally; procurement exercises should be competitive; there should be transparency; and there should be remedies in the event of unfair treatment.

All very fine and commendable.

And some would say that these principles really should be enough, and that as long as a public body accords with these principles, the public body should be able to be able to procure as it wishes.

Just as, say, an employer can recruit who they wish, as long as they do not discriminate against people with certain characteristics.

But.

The law and practice of public procurement goes further than these general principles – at least for high value procurements.

Much, much further.

This is because, in addition to these general principles, there are detailed procedures prescribed for public authorities to follow.

The theory is that these detailed procedures give practical effect to the general principles, by setting out what can and cannot be done at each of the many stages which a public procurement exercise can be broken down into.

And so behold, for example, the 122 sections and 6 schedules over 133 pages of the Public Contracts Regulations 2015.

Behold also the 178 pages of the European Union directive to which those regulations give effect – with no less than 138 recitals.

So, in practice, public procurement exercises can be long and expensive and complicated and legalistic.

And this, in turn, means that many procurement exercises are dominated by the same few mega-providers with specialist bidding teams – you know which companies, with deliberately bland and meaningless names – that can afford the lost costs of an adverse ratio of losing tenders to winning them.

The laws of public procurement can be seen as a well-intentioned way of opening up the government public procurement market that in fact makes things uncompetitive and inaccessible.

*

There are further problems.

Procurement exercises that start with specifications developed by officials can often mean that providers are expected to provide bespoke (and thereby expensive, unrealistic, risky and untried) products and services rather than commercially off-the-shelf products and services.

And suppliers can exploit their relative power at the final stages of a procurement exercise, or after the contract has been entered into, to remove or vary contractual protections for the public body.

Public bodies do not enforce the contractual rights that they do have.

There is also the the issue of the revolving doors between public bodies and purchasers, with many on both sides knowing each other far better than, say, the officials will know those in other parts of the public body.

And so on.

Many problems.

But.

And this is a big but.

*

As one politician once said of a certain political system, it is the worst form of government, except for all the others.

And the same can be said of public procurement.

Anyone who has been involved in the world of public procurement is alert to the problems.

And most public procurement officials do the best they can with the tools that they have got.

The problem is that, if it was not for the law of public procurement, with all its faults, the practice of public procurement would be worse than it is.

If there were no detailed processes for high-value procurements, then there would be even more of a chumocracy, more corruption, more political rather than commercial decisions, more incumbent bias.

The striking thing about the law and practice of public procurement in the United Kingdom is not that there are abuses but that, relatively speaking, there are so few.

If the law of public procurement was stripped away, even just to general principles, there would be little in practice to prevent a free-for-all with public cash.

The challenge for those, like me, who are critical of the law and practice of public procurement is to work out a better (or less bad) way.

And that is hard.

*

Yet sometimes public procurement exercises do need to be flexible.

The detailed processes sometimes need to be set aside.

The current political controversy over the procurement of vaccines seems to show the merits of the quick decision-making of the United Kingdom over the ponderous and inefficient approach of the European Commission. 

If this is the case, then: hurrah!

But for every Bingham there will be many more Hardings.

For every single successful urgent and informal procurement there will be many more botched and extravagant ones.

And this is because there are huge amounts of cash at stake – and public bodies are reliable payers – and where there is such money, there will be corruption and waste.

*

All large-scale procurement is not easy.

Large procurement exercises in the private sector can also be highly problematic – it is just that they are less likely to feature in the news.

This, in many ways, is not an especially ‘public sector’ problem.

And we should, generally, be glad that the law and practice of public procurement works as well as it does.

Yet, there are ways it could be better.

As this blog recently averred, there is actually no good reason why the terms of public contracts should be confidential – at least in respect of allocations of risk and sanctions for non-performance.

Public bodies should also be more ready to use the powers and sanctions they do have under agreements – as it is, it is rare for any public body to ‘go legal’ in a way that a private sector company would do in a similar way with a similar value contract.

There are grounds for legitimate concern that many high-value, elaborate, time-consuming and cumbersome procurement exercises seem perfectly tailored for the benefit of the tender departments of a certain type of mega-suppler.

In essence: far more transparency, and more realism about how current law and practices are abused.

(Leaving the European Union may also be an opportunity for the United Kingdom to revisit the complexity of our domestic procurement regime – though this opportunity will no doubt not be used well.)

*

What should be exciting in politics is the democratic contest between priorities and policies.

And once a priority has been asserted and a policy adopted, the implementation of that priority and policy should not itself be a political issue. 

This is why public procurement should be dull.

(Similarly, it is rarely a good thing when constitutional law, which sets the agreed parameters of political action, becomes the primary focus of sustained political attention, as this means things are not well in the polity.)

But an awareness of the law and practice of public procurement, and not only of its faults but the greater faults which it prevents, should be part of the stock of civic knowledge of every citizen.

Dull things can still be important things.

*****

The title of this post alludes, of course, to this.

*****

If you value this free-to-read and independent legal and policy commentary please do support through the Paypal box above, or become a Patreon subscriber.

Each post takes time, effort, and opportunity cost.

Suggested donation of any amount as a one-off, or of £4.50 upwards on a monthly profile.

This law and policy blog provides a daily post commenting on and contextualising topical law and policy matters – each post is usually published at about 9.30am UK time – though some special posts are published later.

*****

You can also subscribe for each post to be sent by email at the subscription box above (on an internet browser) or on a pulldown list (on mobile).

*****

Comments Policy

This blog enjoys a high standard of comments, many of which are better and more interesting than the posts.

Comments are welcome, but they are pre-moderated.

Comments will not be published if irksome.

The one good thing that may come out of the current row about vaccines export controls

1st February 2021

Since 2016 one unfortunate feature of the Brexit policy (or lack of policy) of the United Kingdom has been the disregard for process.

The European Union brought along the tool of process to its negotiations, while the United Kingdom brought bluster and bravado.

The European Union did better in those negotiations than the United Kingdom. 

But.

Process is not the property of the European Union.

Process can be used for the advantage of other parties, depending on the situation.

Or process can protect a weaker party against a misuse of power.

And the United Kingdom was, before Brexit, quite good at using process in its dealings with its then fellow European Union member states and European Union institutions.

The current row over the invocation of Article 16 by the European Union without it properly having followed the correct (or indeed any) process shows how important it is to hold the European Union to following an agreed process.

Process can matter, a lot.

And process can work to the advantage of the United Kingdom too.

As the United Kingdom develops its post-Brexit relationship with the European Union, through the joint institutions and agreed procedures of the trade and cooperation agreement, the good and thoughtful use of process could become an advantage in respect of the European Union.

The United Kingdom does not have to persist with the loud crashes, bangs and wallops of the Brexit era.

Playing the European Union at its own game, and winning, is also possible.

(Even if the wins are cloaked under the cover of ‘jointly beneficial outcomes’ and other such comforting language.)

*****

If you value this free-to-read and independent legal and policy commentary please do support through the Paypal box above, or become a Patreon subscriber.

Each post takes time, effort, and opportunity cost.

Suggested donation of any amount as a one-off, or of £4.50 upwards on a monthly profile.

This law and policy blog provides a daily post commenting on and contextualising topical law and policy matters – each post is usually published at about 9.30am UK time – though some special posts are published later.

*****

You can also subscribe for each post to be sent by email at the subscription box above (on an internet browser) or on a pulldown list (on mobile).

*****

Comments Policy

This blog enjoys a high standard of comments, many of which are better and more interesting than the posts.

Comments are welcome, but they are pre-moderated.

Comments will not be published if irksome.

What the AstraZeneca agreement actually says

31st January 2021

Was AstraZeneca under a firm obligation to supply the vaccine to the European Commission or was it only under an obligation to use its best efforts?

Only the agreement would tell us for certain.

And a few days ago it did not look like that politically controversial vaccine agreement between the European Commission and AstraZeneca was going to be published.

So, in that circumstance, this blog had a post which, on the basis of public domain information then available – including a published (and redacted) contract with another supplier – sought to put together what might be said about the AstraZeneca agreement.

That post is now superseded, for the AstraZeneca agreement has now been published, though in redacted form.

What this now-published agreement tells us, even more than before, is that AstraZeneca may have been wronged in the political row with the European Commission.

For, just as the European Commission was wrong in invoking article 16 (though that was promptly reversed), it looks as if it was also wrong in how it publicly characterised the contractual obligations of AstraZeneca.

*

Before we get going, some assumptions and provisos.

The AstraZeneca agreement is under the law of Belgium and is subject to the jurisdiction of the courts of Brussels – and I am not a Belgian lawyer.

This means there will be law relevant to the understanding of the agreement of which I will be unaware.

But as I am not providing legal advice but instead mere commentary on an English language legal instrument in the public domain, the fact that the document is under foreign law is not an absolute barrier – though please bear in mind this limitation.

The agreement is also redacted, and there may also be other legal instruments or texts that may be relevant, and so this post is on the basis of the information which is available at the time of writing.

I am also aware that there are versions of the agreement on the internet which purport to show the redacted text but I have not looked at any of these and I respect the confidentiality of the parties: this post is on the basis of the text published by the European Commission.

What follows is an account of what the AstraZeneca agreement says by an English legal commentator with some experience as a lawyer in commercial contracts and public procurement matters.

*

First, the parties.

The agreement is between the European Commission, acting on behalf of European Union member states, and AstraZeneca AB, incorporated in Sweden.

That this is the AstraZeneca entity that is party to the agreement may be significant, for (all other things being equal) only that entity will be bound by obligations on AstraZeneca in the agreement – and not any other AstraZeneca entity.

As we will see, this possible distinction may be important (or at least of interest) depending on which AstraZeneca entity is party to the prior agreement for the supply of the vaccine in the United Kingdom.

*

Moving on from the parties, we come next to the recitals.

Recitals are curious things in legal instruments – and tend to be far more popular (and numerous) in continental Europe than in England.

(Some European Union legal instruments have recitals that go on for longer than the operative provisions.)

The notion is that a recital does not (or should not) create a legal obligation in and of itself.

Instead, a recital should tell those considering the instrument what the background is to the document and thereby it gives a steer to how the operative provisions should be construed.

Recitals are thereby (or should be) an aid to construction and interpretation of a legal instrument.

(That said, in twenty years of experience of practical commercial law, I have seen recitals used for all sorts of naughty purposes.)

The key recitals in the AstraZeneca agreement are the following:

These recitals set out the shared understanding of the European Commission and AstraZeneca as at the time of the agreement (which was signed by both parties on 27 August 2020).

A breach of a recital – that is, if a recital is not factually true – does not (at least under English law) trigger any automatic remedy.

But a recital can have effect when it comes to construing the effects of other provisions.

The first of the three quoted recitals is interesting in that it shows the European Commission is already aware that AstraZeneca is scaling up its capacity for the broadest possible availability, separately from this agreement.

The second quoted recital then expressly affirms that this agreement is only ‘part’ of that scale-up.

And the second quoted recital introduces the phrase that has become famous as part of the current political controversy: ‘Best Reasonable Efforts’.

In particular, the recital records that AstraZeneca is committed to using ‘Best Reasonable Efforts’ to build capacity to manufacture 300 million ‘initial’ doses.  

The third quoted recital then says the supply of those ‘initial’ doses will be in accordance with the terms of the agreement.

(As these are only recitals, not that much – or perhaps anything – can be made of the second quoted recital not referring to ‘according to the terms of the agreement’ but the third quoted recital then doing so, but it is a curious omission.)

*

So much for the recitals.

But before we go to the operative obligations, we need to look at the definitions and at one definition in particular: ‘Best Reasonable Efforts’.

Here, unlike in English law agreements which tend to leave ‘best endeavours’ and ‘reasonable endeavours’ to a court to sort out (though I did once catch one naughty ‘Magic Circle’ law firm trying to expressly define in a contract the more onerous ‘best endeavours’ to mean the less onerous ‘reasonable endeavours’), the parties in this agreement have agreed a definition of ‘Best Reasonable Efforts’.

Indeed, like New York, so enamoured are the parties of the concept, the parties have defined the term twice.

There are ‘Best Reasonable Efforts’ for the commission and ‘Best Reasonable Efforts’ for AstraZeneca.

As we are concerned with the supply obligations of AstraZeneca, we need to know what the term means for them:

Here we need to remember that a definition is only a definition, and that the important thing is how the definition is employed in an operative clause.

But when we do see the term in an operative clause, all of this definition will be applicable.

And so there is a significant difference between an absolute obligation (‘[x] shall do [y]’) and a qualified obligation ‘[x] shall use Best Reasonable Efforts to do [y]’ – for the latter comes with all the baggage of the defined term.

*

Now come the operative clauses.

This being a bilateral supply agreement, the primary obligations will be for one party to supply a thing, and for the other party to pay for it.

In very (very) general terms, many of the other provisions of the agreement will be of secondary importance to these two primary obligations.

This post is not concerned with the payment obligations, many of which are in any case redacted, and so we will look at the supply obligations.

These mainly are in article 5.

The primary obligation of the supplier under this agreement is to do two things: to manufacture (so that the vaccine is ready for distribution) and to deliver.

And, in respect of the initial doses, this dual obligation is in article 5.1:

We can also see that this provision makes both the manufacturing-ready-for-distribution and delivery obligations for the initial doses of the vaccine subject to ‘Best Reasonable Efforts’.

(Articles 5.2 and 5.3 then deal with optional orders for further and additional doses.)

But then there is a further clause – which sadly warrants an Alan Hansen wince at its awkward drafting.

Article 5.4 provides:

Is this also a primary supply obligation?

Perhaps it is, and article 5.1 goes only to distribution and delivery, but it seems to me that the intention is that article 5.4 deals only with the location of the manufacturing (hence (a) the heading of article 5.4, though headings usually are not to be used for interpreting contracts, and (b) the text in the article which follows ‘provided’) – rather than it being the primary manufacturing obligation itself.

And the placing of the reference in that article to the United Kingdom is also odd, though this was probably a late amendment to make sure that the provision was Brexit-proof.

But for the purpose of this post, it does not really matter, as this obligation too is subject to ‘Best Reasonable Efforts’.

*

But, as the jurist Jimmy Cricket would aver, there is more.

If we now go down to article 13 we will see the representations and warranties of AstraZeneca:

And we can see at article 13(1)(e) what may seem to be a relevant promise by AstraZeneca.

Did AstraZeneca fail to fulfil its contractual obligations to the European Union by reason of conflict with obligations to third parties?

Did such obligations to third parties impede AstraZeneca’s performance of its obligations under this agreement?

A breach of article 13(1)(e) by AstraZeneca would be legally consequential – this is not just a recital – and (at least under English law) a breach would entitle the European Commission to compensation, if it could show that it caused damage, or even to rescind the agreement.

But it is not clear that the fact that AstraZeneca did have a prior agreement in respect of the United Kingdom such that it would mean that AstraZeneca was in breach of article 13(1)(e).

Article 13(1)(e) does not say that AstraZeneca promises to not have any other such obligations but that those obligations will not conflict with this agreement or impede performance of the obligations under this agreement.

And the relevant obligations under this agreement are, as defined, simply to use ‘Best Reasonable Efforts’ – so the other obligations would have to conflict with or impede not some absolute obligation, but only an obligation to use ‘Best Reasonable Efforts’.

Furthermore, and as we have already seen with the recitals, the European Commission expressly acknowledged that AstraZeneca was scaling-up manufacture generally, and that only part of this was for the European Commission.

That AstraZeneca had a prior agreement in respect of the United Kingdom was also well-publicised and it cannot be seriously posited as something unknown by and unforeseen to the commission.

Indeed, AstraZeneca was in a position to scale-up and so on because of this prior agreement.

In all these circumstances, it would seem to me to be difficult for the European Commission to rely on article 13(1)(e), and even if it could, it is not clear where that would get the commission.

And, of course, there would also be the possible difficulty that the Swedish AstraZeneca entity that accepted the burden of article 13(1)(e) is not even the AstraZeneca entity that has entered into any obligations in respect of the United Kingdom.

*

So, we can now go back to Wednesday 27th January 2021, when the relevant European Commissioner said:

‘The view that [AstraZeneca] is not obliged to deliver because we signed a ‘best effort’ agreement is neither correct nor is it acceptable.’

In view of what that agreement actually says – recitals, definitions, primary obligations, warranties, representations, and so on – there is reason to believe that this statement by the commissioner was incorrect and misleading.

As long as AstraZeneca fulfilled the definition of ‘Best Reasonable Efforts’ in respect of its obligations under article 5(1) of the agreement, then AstraZeneca has performed its side of the bargain.

*****

If you value this free-to-read and independent legal and policy commentary please do support through the Paypal box above, or become a Patreon subscriber.

Each post takes time, effort, and opportunity cost.

Suggested donation of any amount as a one-off, or of £4.50 upwards on a monthly profile.

This law and policy blog provides a daily post commenting on and contextualising topical law and policy matters – each post is usually published at about 9.30am UK time – though some special posts are published later.

*****

You can also subscribe for each post to be sent by email at the subscription box above (on an internet browser) or on a pulldown list (on mobile).

*****

Comments Policy

This blog enjoys a high standard of comments, many of which are better and more interesting than the posts.

Comments are welcome, but they are pre-moderated.

Comments will not be published if irksome.

 

 

 

 

 

 

 

What is Article 16 of the Northern Irish Protocol – and what on Earth was the European Commission thinking? (Includes a copy of the now deleted proposed regulation.)

30th January 20211

After four years or so of chronicling the various self-inflicted unforced errors of the United Kingdom, and the better decisions at each stage of Brexit by the European Union, it is kind of refreshing to see the European Commission commit a pratfall.

Of course, this is a grave situation, and we should be terribly earnest, but still: it is salutary to be reminded that no entity is perfect.

That said, some partisans – this time for the European Union – will maintain that there was no error and that the European Commission was entitled yesterday to invoke article 16 of the Irish protocol.

Unfortunately for such partisans, the European Commission did a quick reverse-ermine last night to un-invoke article 16.

This was quite the spectacle for onlookers at the end of what was, on any view, not a good week for the European Commission.

But what is article 16?

And what on Earth was the European Commission thinking?

And how can the European Commission explain (away) recital 17 of the (now deleted) proposed regulation in question?

*

One of the blessings of Brexit is dealing with ‘articles’ of international legal instruments – most famously article 50 of the treaty on European Union.

The word ‘article’ is somehow grander than the more mundane ‘section’ and the plebeian ‘clause’.

And indeed articles tend to more self-contained as legal provisions – sometimes like micro legal instruments within macro legal instruments.

Article 16 is within the Irish protocol, which in turn is a protocol to the withdrawal agreement.

Instruments within instruments within instruments.

The article provides in its entirety:

The article is entitled ‘Safeguards’ – but straight away you will see that the provision is itself subject to its own safeguards.

In paragraph 1, the trigger for the safeguards has to be a serious situation that is likely to persist.

And – it then provides that any safeguards will be ‘restricted’ to what is ‘strictly necessary’ for the purpose of remedying that particular serious situation.

And – ‘priority’ shall be given to what measures that cause the least disturbance.

And – in paragraph 2, any imbalances caused by the uses of the safeguards can be addressed.

And – in paragraph 3, there is a further process to be followed, as set out in an annex.

Annex 7 then in turn supplements the substantive limits to the use of Article 16 safeguards with procedural protections:

Even in the event of ‘exceptional circumstances’ under point 3 of this annex, there is still a procedure to be followed.

Safeguards within safeguards within safeguards, and so on.

In summary: invoking article 16 is not to be done casually or by mere oversight.

It is not a red button that can be pressed by accident.

There are substantive and procedural conditions to be fulfilled before it can be invoked.

And the European Commission will know this – for two reasons.

First, article 16 is a provision which the European Union recently agreed.

And second, the European Union is a creature of law itself and is thereby bound by the letter of the law in what it can and cannot do.

The essence of the European Union is process, or it is nothing.

*

Given the careful substantive and procedural protections of article 16 it came as a bit of a surprise when reports emerged yesterday that the European Commission was invoking the provision – and was doing so in a highly charged political situation.

As the Guardian reported:

Even the archbishop of Canterbury.

Imagine that.

*

Although the invocation of article 16 was widely reported by major news sites – and was not denied by the commission – there appears to have been no formal announcement by the commission.

Indeed, there appears to be no ‘on the record’ confirmation that it was invoked.

But.

What happened is that a proposed European Union regulation appears to have been published.

The regulation (in draft form) appears to be at the internet archive.

And, while I was writing this post, a reliable source has provided me with this ‘final’ copy that was deftly downloaded before the European Commission deleted the regulation.

tradoc_159398 (1)

*

Recital 16 – a formal recital! – of this regulation has the European Commission asserting that the quantitive restriction on exports was ‘justified’ under article 16, and that the justification was because it was ‘in order to avert serious societal difficulties due to a lack of supply threatening to disturb the orderly implementation of the vaccination campaigns in the Member States’.

This is significant, as the recital indicates that the justification exercise has already been conducted – that the recital describes a thing that has already taken place.

But asserting the safeguard is justified is not the same as showing that the substantive requirements of article 16 have been met: was it ‘restricted’ to what is ‘strictly necessary’ for the purpose of remedying that particular situation, and was ‘priority’ given to what measures that cause the least disturbance?

Was the measure even within the scope of the Irish protocol in the first place?

And was the annex 7 procedure followed – or even considered?

What we do know, however, is that formal recitals to legal instruments do not come about by accident – even when those regulations are in draft form, let alone ‘final’ form.

Somebody somewhere in the European Commission had to have made a decision for that recital to be part of the regulation.

And that can be most plausibly explained by someone at the European Commission having decided to invoke article 16.

*

The invocation did not last long.

The European Commission issued a late-night press release stating that it was not triggering article 16:

The key sentence is unqualified (and is curiously in the present tense): ‘The Commission is not triggering the safeguard clause.’

*

The known facts point to article 16 having been triggered – that is the most plausible explantation for recital 16 to the proposed regulation – but also point to the commission not having followed annex 7.

In the immediate political context of concerns about ‘vaccine nationalism’ and in the broader context of the border in Ireland after Brexit, it was an unwise move by the European commission.

(Though, as averred at the head of this post, it was also good to see that the European Union can blunder as horribly as the United Kingdom.)

Perhaps the European Commission now hopes that this mistake will fade and disappear.

Perhaps both sides will now take more care before even considering article 16 safeguards.

Or perhaps all this is, in effect, a dress rehearsal for the political crisis when either side does go through with invoking article 16.

Brace, brace.

*****

If you value this free-to-read and independent legal and policy commentary please do support through the Paypal box above, or become a Patreon subscriber.

Each post takes time, effort, and opportunity cost.

Suggested donation of any amount as a one-off, or of £4.50 upwards on a monthly profile.

This law and policy blog provides a daily post commenting on and contextualising topical law and policy matters – each post is usually published at about 9.30am UK time – though some special posts are published later.

*****

You can also subscribe for each post to be sent by email at the subscription box above (on an internet browser) or on a pulldown list (on mobile).

*****

Comments Policy

This blog enjoys a high standard of comments, many of which are better and more interesting than the posts.

Comments are welcome, but they are pre-moderated.

Comments will not be published if irksome.

 

 

 

 

 

 

 

 

 

 

 

 

 

There is no good reason why any public contracts are not in the public domain – the AstraZeneca vaccine contract or otherwise

29th January 2021

Yesterday this blog set out in detail what could be worked out form public domain sources about the politically controversial AstraZeneca contract for the provision of vaccines to the European Union.

That post was an exercise in detective work, aided greatly by the publication of a redacted version of a contract with another supplier, the terms of which fitted neatly with the details disclosed by the European commissioner and the CEO of AstraZeneca in their public bickering.

In the comments below that post, some commenters were able to glean even more from public sources, including from further examination of the published redacted contract (and many of the commenters at this blog are awesome and experts in their fields).

It was an interesting and indeed fascinating exercise.

But.

It was something which should not have been needed.

For the actual contract should have been in the public domain to begin with.

*

There is no good reason why public contracts are not in the public domain.

(By ‘public contracts’ I mean contracts for the supply of goods, services and works –  including for major projects – to public authorities.)

There are (supposed) reasons – the cant phrase ‘commercially sensitive’ is often the excuse – but no good reasons.

But there are two good reasons why public contracts should be in the public domain.

*

First, the goods, services and works supplied under public contracts are paid for with public money.

And public authorities tend to be reliable payers.

Fortunes can and often are made from lucrative public contracts.

It is not unusual for a valuable public contract to be the security for all sorts of further commercial transactions, so dependable is a public contract as a high-value revenue stream.

A good part of the wealth of the City of London, and of those currently enjoying lockdown life in expensive suburbs, is based not on the hard cut-and-thrust of private sector life but on the soft cushions of public sector contracts.

(And this dependency culture contrasts with the complaints of backbench government supporters about the supposed dependency-culture of free school meals.)

The price of this access to public money should be the burden of transparency.

A private sector company should not have the benefit of these lucrative and low-risk public contracts, and also have the contract shielded from public scrutiny.

*

Second, turning from revenue to performance, there is a public interest in publication of how any public contract addresses issues of risk allocation and sanctions for breach.

This is not about prices – as the European commission showed in publication of the redacted vaccine supply contract, it is perfectly possible to publish the substance of how a contract manages risk without publishing (real or imagined) ‘commercially sensitive’ material.

How does the contract deal with foreseeable risks?

How does the contract allocate the burden of risks between the parties?

What happens if a provider is unable to provide the agreed goods, services or works?

This is the meat of any substantial contract – not just the list of what is bought and for what price.

If that is all a contract is then there would be no need for any contract to be more than a page long.

The bulk of a contract, other than for the most simple of transactions, deals with what happens when things do not turn out as agreed – and what can happen next.

And in any public contract what happens next in the event of any non-performance is as much a matter in which the public interest is engaged as in the performance.

But when a contract is – in its entirety – hidden from public view, the public have no knowledge of how that contract allocates risk – or indeed whether the contract allocates risk at all.

This in turn means there will be contracts where the risk of non-performance is loaded entirely on the public authority.

And with such contracts the supplier will not only have the benefit of a lucrative revenue stream but also the benefit of it being legally risk-free.

A public supply contract for cakes, and for the service of eating them.

*

Publication of such contracts would not, at a stroke, mean that problems of non-performance or overcharging will go away.

Public procurement has many problems, and non-transparency is only one.

But the ‘commercially sensitive’ cloak of invisibility serves no one other than the public officials and suppliers who are shielded from any meaningful scrutiny.

A public official can sign a bad deal (and then sign amendment after amendment to that deal), and no one will find out because it is all ‘commercially sensitive’.

A supplier can get away with either bad contracts or terms not being enforced against them, again because it would be commercially sensitive’ for the terms of the contract to be published.

*

Some of those in public procurement will view the above as harsh – and will protest: how could you be so offensive and so doubtful.

But such displays of (non-commercial) sensitivity are not a good reason for non-disclosure of public contracts.

If all is well, then nothing will be lost with publication of public contracts – and publication will provided public confidence that good contracts are being entered into at fair prices and with effective and enforceable allocations of risk.

And if all is not well, then…well.

*****

If you value this free-to-read and independent legal and policy commentary please do support through the Paypal box above, or become a Patreon subscriber.

Each post takes time, effort, and opportunity cost.

Suggested donation of any amount as a one-off, or of £4.50 upwards on a monthly profile.

This law and policy blog provides a daily post commenting on and contextualising topical law and policy matters – each post is usually published at about 9.30am UK time – though some special posts are published later.

*****

You can also subscribe for each post to be sent by email at the subscription box above (on an internet browser) or on a pulldown list (on mobile).

*****

Comments Policy

This blog enjoys a high standard of comments, many of which are better and more interesting than the posts.

Comments are welcome, but they are pre-moderated.

Comments will not be published if irksome.

 

What can be worked out about the ‘best efforts’ clause in the AstraZeneca vaccine supply agreement?

28th January 2021

Over at the Financial Times I have done a brief summary post on the ‘best efforts’ clause that features in the current public row between the European Commission and AstraZeneca – please click and read here.

This post sets out the ‘workings out’ for that summary, based on the information available to me this morning.

*

First, what is the public row?

The inkling of the row was on (Friday) 22nd January 2021: EU hit by delay to Oxford/AstraZeneca vaccine delivery.

The European Commissioner responsible in respect of the vaccine tweeted:

Here, note two things.

First, the information comes from AstraZeneca – in effect, the European Commission is being formally notified of a delay.

Second, the delays are against a ‘forecast’.

As we will see below, both of those things may be significant.

*

We now move to (Monday) 25th January 2021, and to the published remarks of the commissioner.

In particular, this passage:

‘Last Friday, the company AstraZeneca surprisingly informed the Commission and the European Union Member States that it intends to supply considerably fewer doses in the coming weeks than agreed and announced.

‘This new schedule is not acceptable to the European Union.’

Here note the following.

First, the ‘forecast’ is now a thing which was ‘agreed and announced’.

Second, the information coming from AstraZeneca is described as ‘surprising’.

Third, the reference to a ‘new schedule’.

We will come back to these details.

*

Now the interview with the CEO of AstroZeneca at la Repubblica dated (Tuesday) 26th January 2021 (and I rely on that site’s English translation).

The CEO is quoted as saying in part of his response to a question as to whether there is a feasible basis for a potential legal action against AstraZeneca:

“I can only tell you what’s in their contract. And the contract is very clear. Our commitment is, I am quoting, “our best effort”.’

*

Now back to the European commissioner, on (Wednesday) 27th January 2021 and further published remarks:

‘The view that the company is not obliged to deliver because we signed a ‘best effort’ agreement is neither correct nor is it acceptable.

‘We signed an Advance Purchase Agreement for a product which at the time did not exist, and which still today is not yet authorised. And we signed it precisely to ensure that the company builds the manufacturing capacity to produce the vaccine early, so that they can deliver a certain volume of doses the day that it is authorised.’

Note here the ambiguous sentence about what was signed.

Did the commission not sign an agreement with a ‘best effort clause’?

(Which was my first impression.)

Or did the commission sign a ‘best effort’ agreement but this does not remove the obligation of AstraZeneca to deliver the vaccine?

(Which is also a possible meaning of the statement, but not a meaning that would be immediately obvious to most people.) 

Also note the express reference to this being an ‘Advance Purchase Agreement’.

*

The advance purchase agreements are part of the European Commission’s vaccine policy announced last June.

In a detailed paper, both the nature and structure of these agreements are set out:

‘These agreements will be negotiated with individual companies according to their specific needs and with the aim of supporting and securing an adequate supply of vaccines. They will de-risk the necessary investments related to both vaccine development and clinical trials, and the preparation of the at-scale production capacity along the entire vaccine production chain which is required for a rapid deployment of sufficient doses of an eventual vaccine in the EU and globally. The conditions of the contract will reflect the balance between the prospect of the producer providing a safe and effective vaccine quickly and the investment needed to deploy the vaccine on the European market.’

The agreements were therefore (and were intended to be) balanced allocations of risk between the commission and the supplier.

These agreement would thereby not be bog-standard standard-form supply contracts, but agreements alert to and mindful of the particular risks in respect of the manufacture and the supply of the vaccine.

*

The agreement between the commission and Astra Zeneca is not in the public domain.

But what is in the public domain – helpfully – is a redacted version of an advance purchase agreement between the commission and another supplier.

The link to this agreement was (I am told by the commission press office) published on 19th January 2021 and so was published before this row.

This means that the redactions would not be informed by the subsequent row.

The agreement is here.

Of course, this is not the agreement between the commission and AstraZeneca, and it would only be sight of that contract that would mean you could say what was agreed with absolute confidence.

But, that said, a careful reading of this published contract is revealing.

*

Before we look at the contract, an assumption: the advance purchase agreement with AstraZeneca will be substantially similar to the published contract.

The contracts will not be absolutely identical, because there will be negotiated commercial and other terms (which are probably the redacted parts of the published contact).

And I think it is safe to assume that the agreement will not be on AstraZeneca’s own terms, given the importance the commission placed on the advance purchase agreements being a careful balance for all concerned.

Therefore I am assuming that the the advance purchase agreement with AstraZeneca and the published contract will have many identical and similar terms, even if not absolutely the same.

*

If we look at the published contract, and search, you will quickly find that ‘reasonable best efforts’ is a defined term.

(Some commentators, who have also seen the agreement, start and then sadly finish with just this definition – but as you will see, a defined term is only one step in understanding what is going on.)

The definition of the term is detailed, and indeed rather elaborate:

The size and scope of the definition tells us two things.

First, the parties did not want to leave it to the court (which in this case is the Belgian court) to construe what is a ‘reasonable best effort’ – the parties have defined it for themselves.

And second, such a detailed and elaborate definition in respect of a key component of the contract is likely to have been used in all the advance purchase agreements, not just the published one.

The fact it is not redacted in the published contract also indicates it is not a bespoke definition for just that particular contract.

*

But.

Any defined term is only as important as the operative provision in which it is used.

(This is where some other commentators have not taken the further step.)

A defined term does not exist in a vacuum.

‘Reasonable best efforts’ is not a free-floating term, to be produced like a joker in a card game.

It will be used, and its effect limited, in particular provisions.

And a search of the published contract shows that this detailed and elaborate definition is used only once (at least in the not-redacted text).

This is article 1.3 of the published agreement:

Here we will see that ‘reasonable best efforts’ is used for two things:

‘(i) to obtain EU marketing authorisation for the Product and (ii) to establish sufficient manufacturing capacities to enable the manufacturing and supply of the contractually agreed volumes of the Product to the participating Member States in accordance with the estimated delivery schedule set out below in Article I.11 once at least a conditional EU marketing authorisation has been granted.’

This means that ‘reasonable best efforts’ is only relevant for two specific purposes.

If the published contract is similar to the AstraZeneca contract, then it would be the second limb of this provision which would be relevant.

AstraZeneca would have an obligation to use ‘reasonable best efforts’ to ‘establish sufficient manufacturing capacities’ for the manufacture and supply of the vaccines ‘in accordance with the estimated delivery schedule‘.

Note the mention of the schedule, which ties in with the commissioner’s published remarks.

And note also the mention of ‘to establish sufficient manufacturing capacities’ – which would not mean, say, a diversion of what is manufactured once there are capacities.

*

And there is more.

If we now look at what happens with delays to the ‘estimated delivery schedule’ we go down to article 1.12 of the published agreement:

Here – significantly – both parties explicitly agree in article 1.12.1 that there is a risk of delays in production.

And in the event of such a delay there is an obligation under article 1.12.2 on the supplier to notify the commission and to provide a revised schedule.

Going back to what has happened in the last week, and assuming the contract with AstraZeneca is on similar terms to the published contract, we can see this is exactly what happened.

AstraZeneca informed the commission that it could not keep to the estimated delivery schedule on Friday 22nd January 2021 – and this accords with the mentions of ‘forecast’ and ‘schedule’ by the commissioner.

There was then push-back (to say the least) from the commission, and AstraZeneca – as described by the CEO – sought to rely on the estimated delivery schedule being subject to the ‘best efforts’ provision.

And the commission responded by denying that that ‘best efforts’ provision covers the delay – presumably because AstraZeneca has the capacity but is diverting it from the EU.

*

Of course, without the actual contract entered into with AstraZeneca we cannot be certain.

But it is telling how neatly the details provided in the public row fit with the steps of the terms of the published contract.

Unless there is something significant about which we do not know, it is more likely than not that the details provided in the public row mean that the contract with AstraZeneca are materially the same as that in the public contract.

If the reasoning in this post is correct then the following two things can be contended.

First, the remark of the commissioner that ‘[t]he view that the company is not obliged to deliver because we signed a ‘best effort’ agreement is neither correct nor is it acceptable” is capable of giving a misleading impression – for the agreement did have a ‘best efforts’ provision.

And second, the existence of that ‘best efforts’ provision may not be that helpful to AstraZeneca, if the correct construction of the contract is that it does not cover diverted capacity as opposed to lack of capacity – and so citing the ‘best efforts’ provision will not be enough to meet the commission’s complaint.

*

The moral of the story, of course, is that such public supply contracts should be published as a matter of course – and there is no good reason for such contracts not to be published.

The benefit of access to public money should be the burden of transparency.

But that is a far wider issue to which this blog may return.

*****

If you value this free-to-read and independent legal and policy commentary please do support through the Paypal box above, or become a Patreon subscriber.

Each post takes time, effort, and opportunity cost.

Suggested donation of any amount as a one-off, or of £4.50 upwards on a monthly profile.

This law and policy blog provides a daily post commenting on and contextualising topical law and policy matters – each post is usually published at about 9.30am UK time – though some special posts are published later.

*****

You can also subscribe for each post to be sent by email at the subscription box above (on an internet browser) or on a pulldown list (on mobile).

*****

Comments Policy

This blog enjoys a high standard of comments, many of which are better and more interesting than the posts.

Comments are welcome, but they are pre-moderated.

Comments will not be published if irksome.

 

 

 

 

 

 

 

 

 

 

 

 

 

Legal words v everyday words – how can the killing of six prisoners between the presidential election and inauguration not be a ‘cruel and unusual’ punishment?

27th January 2021

Over at Prospect my column this month is on the grim topic of capital punishment and how former President Trump revived federal executions in the last seven months of his presidency – for my article click and look here.

In this post today I want to expand on the issue I touch on in the introductory paragraphs of that article: what is a ‘cruel and unusual punishment’?

*

The reason this matters, of course, is the eighth amendment to the constitution of the United States, the relevant text of which provides: 

‘nor cruel and unusual punishments inflicted.’  

So if a punishment is cruel and unusual (and note it is ‘and’ and not ‘or’) then it is not only prohibited but also unconstitutional.

Some would contend (in my view rightly) that any use of the death sentence is, at least in modern times, a ‘cruel and unusual punishment’.

But here another part of the constitution is engaged.

The fifth amendment provides, among other things:

‘nor shall any person…be deprived of life, liberty, or property, without due process of law’.

This means that the constitution envisages that a person can be deprived of their life by process of law.

And as United States prosecutors, and supporters of the death penalty often point out, the fifth and the eighth amendments were adopted at the same time (as part of the bill of rights) and thereby should be read together.

Of course, there is a certain irony – cruel perhaps – that the fifth amendment was intended to have a generally liberal effect now has, in respect of capital punishment, an illiberal effect.

So the constitutional position is that capital punishment is permitted (fifth amendment) as long as it is not ‘cruel and unusual’ (eighth amendment).

*

In my Prospect column I argue, by the modern everyday meaning of the words ‘cruel’ and ‘unusual’, that the six executions after Trump was defeated and before the new President Joseph Biden was inaugurated were indeed unusual and cruel.

This argument has three bases.

First, once Trump was defeated it was plain that there would be a new president within weeks who was pledged to end federal executions.

And so if the executions did not take place by 20th January 2021 then the prisoner would not be killed.

They would still be alive today.

Second, federal executions are not usual

Indeed, before Trump there had not been any federal executions for seventeen years and, before then, only three executions since 1966.

Click and have a look at this table.

Of course, executions take place in individual states – though twenty-two states have abolished the death penalty and in a further thirteen states there is either a formal or an informal moratorium.

But at a federal level executions were not, between 1966 and 2020, usual.

And by definition, what is not usual is unusual. 

Third, these final six executions were (especially) cruel.

The prisoner – and those charged with killing the prisoner – knew that there was now a race against time.

This deliberate putting to death of a human being had to be done within days, if it was to be done at all.

The circumstances of the six executions after the election but before inauguration indeed amounted to the application of mental torture as part of the punishment.

*

But.

Although words have everyday meanings when those words are in a formal legal instrument, those words also have special legal meanings.

And the words ‘cruel’ and ‘unusual’ have been considered by the United States courts again and again.

Caselaw accumulates like barnacles on a shipwreck, so that little or nothing can now be seen of the original vessel.

The general position now is that whether a punishment is ‘cruel’ goes to the technique used at the point of death (and not the period leading to the execution), and if the punishment is still in use then it cannot be ‘unusual’ (which is fairly circular argument).

(The latest significant case in this grisly caselaw is here.)

What it is plain is that the wording of the constitutional prohibition is not autonomous – that it cannot be used in any given situation, free from the weight of caselaw.

A thing is only ‘cruel’ and/or ‘unusual’ if it accords with what these words mean as a matter of 230 years of caselaw, and not what those words mean in everyday discourse.

And this is both a merit and a flaw of placing rights in formal written instruments, such a a bill of rights.

On one hand, a person can point to the right and say with certainty that they have these fundamental protections; but on the other hand, formality can quickly become rigidity.

There is no easy solution to this problem of how one protects rights with a living, evolving legal instrument.

*

None of this is to aver that the executions between the election and the inauguration were unlawful and unconstitutional – the fact that the United States supreme court did not prevent those killings indicates that the punishments were lawful and constitutional.

Nor does this post contend that the constitutional law of the United States can easily be recast so as to render such executions as unlawful and unconstitutional.

The purpose of this post is to illustrate the gap between everyday language and precise legal terminology: that, in these instances, things that are plainly cruel and usual are not ‘cruel and unusual’.

This leads to the wider point about using the law to guarantee rights and freedoms: a general legal instrument quickly attracts caselaw, and that caselaw scopes and often limits the meaning of that instrument.

And so one can end up with the vile spectacle of six human beings being deliberately slaughtered before 20th January 2021 because they would be safe from slaughter if they managed to live beyond that date, and that this horrific episode was, as a matter of law, neither cruel nor unusual.

*****

If you value the free-to-read and independent legal and policy commentary please do support through the Paypal box above, or become a Patreon subscriber.

Suggested donation of any amount as a one-off, or of £4.50 upwards on a monthly profile.

This law and policy blog provides a daily post commenting on and contextualising topical law and policy matters – each post is published at about 9.30am UK time.

Each post takes time, effort, and opportunity cost.

*****

You can also subscribe for each post to be sent by email at the subscription box above (on an internet browser) or on a pulldown list (on mobile).

*****

Comments Policy

This blog enjoys a high standard of comments, many of which are better and more interesting than the posts.

Comments are welcome, but they are pre-moderated.

Comments will not be published if irksome.

Why the first paragraph of the lawsuit brought by Dominion Voting Systems against Rudolph Giuliani is a splendid piece of legal drafting

26th January 2021

You would need a heart of stone not to laugh like a drain at the lawsuit brought by Dominion Voting Systems against Rudolph Giuilani.

The pleading is worth reading for its own sake, and the first paragraph – which, as this post will show, rewards re-reading – is a cracker.

But once one eventually stops laughing, what should one make of it?

Of course, the defendant Rudolph Giuilani is now regarded by many as a figure of political fun, a villain in the Trump pantomime.

But principle is – or should be – blind to the person to whom it applies.

So here is a thought experiment.

Imagine – for the sake of argument and exposition – that there was a corporation that provided voting machines and, unlike the plaintiff in this case, there was a serious and consequential issue as to the efficacy of the equipment.

And imagine that the political or media figure bringing loud attention to this issue was not the defendant in this situation but instead a credible and likeable politician or journalist.

Would you still clap and cheer if that noble figure was faced with a 107-page legal claim for $651,735,000 or some other absurdly precise amount?

Or would you re-tweet furiously about threats by corporates to whistleblowing and freedom of expression?

*

So how can the court tell the good cases from the bad?

How can the court strike the right balance?

*

This thread from American lawyer Mike Dunford sets out the legal challenges for Dominion Voting Systems:

And as would be the position with a similar case in England and Wales, you will see that the legal issue quickly becomes one of showing malice – and there it is called ‘actual malice’:

*

At this point the non-lawyer will ask, understandably: what is malice?

And a lawyer will respond, frustratingly: it all depends.

But here it is interesting to now go back to the first paragraph of the the legal pleading of Dominion Voting System (and this is why it is worth re-reading):

“During a court hearing contesting the results of the 2020 election in Pennsylvania, Rudy Giuliani admitted that the Trump Campaign “doesn’t plead fraud” and that “this is not a fraud case.” Although he was unwilling to make false election fraud claims about Dominion and its voting machines in a court of law because he knew those allegations are false, he and his allies manufactured and disseminated the “Big Lie,” which foreseeably went viral and deceived millions of people into believing that Dominion had stolen their votes and fixed the election. Giuliani reportedly demanded $20,000 per day for that Big Lie. But he also cashed in by hosting a podcast where he exploited election falsehoods to market gold coins, supplements, cigars, and protection from “cyberthieves.” Even after the United States Capitol had been stormed by rioters who had been deceived by Giuliani and his allies, Giuliani shirked responsibility for the consequences of his words and repeated the Big Lie again.”

This is not just racy narrative – if you look carefully you will see that it is a clever attempt to show malice.

Giuliani said a thing he knew he could not say in court; he knew it would go viral; he had a financial incentive; and he was irresponsible in respect of its consequences.

Every sentence – every clause – of that well-crafted first paragraph is serving a purpose in showing that there was ‘actual malice’.

It is a lovely piece of legal drafting – enough to make one want to clap and cheer, regardless of the identity of the defendant.

*

Corporations – especially those providing public services or supplying equipment for use in public services – should not have it easy when it comes to making legal threats.

Even when they are threatening pantomime villains.

Public figures, especially those in the worlds of politics and media, should have some protection when they are complaining of such corporations.

Even when those figures are pantomime villains.

The purpose of the law in these situations is to strike a balance – to provide for what both sides would need to show in court.

Here the corporation – rightly – cannot just sue because of damaging false statements, it may also need to show that there was malice.

And the lesson of the first paragraph of the pleading and of the rest of the complaint is that in certain circumstances this can be shown, at least arguably.

What comes of this case cannot be guessed at this time – and most civil claims tend to settle.

But Giuliani has a genuine legal fight on his hands here.

And you would need a heart of stone not to laugh like a drain.

*****

If you value the free-to-read and independent legal and policy commentary please do support through the Paypal box above, or become a Patreon subscriber.

Suggested donation of any amount as a one-off, or of £4.50 upwards on a monthly profile.

This law and policy blog provides a daily post commenting on and contextualising topical law and policy matters – each post is published at about 9.30am UK time.

Each post takes time, effort, and opportunity cost.

*****

You can also subscribe for each post to be sent by email at the subscription box above (on an internet browser) or on a pulldown list (on mobile).

*****

Comments Policy

This blog enjoys a high standard of comments, many of which are better and more interesting than the posts.

Comments are welcome, but they are pre-moderated.

Comments will not be published if irksome.